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Abstract
Background: The circulating level of the peptide hormone 
insulin-like factor 3 (INSL3) is a promising diagnostic 
marker reflecting Leydig cell function in the male. Few 
commercial immunoassays of varying quality exist. There-
fore, we decided to develop and validate a precise method 
for quantification of INSL3 by mass spectrometry.
Methods: We developed an assay in which the INSL3 
A-chain is released from the INSL3 A-B heterodimer by 
chemical reduction and alkylation. The alkylated INSL3 
A-chain is quantitated by liquid chromatography-tandem 
mass spectrometry (LC-MS/MS), as substitute for serum 
INSL3. The method was compared to a validated and sen-
sitive in-house serum INSL3 immunoassay using 97 serum 
samples from 12 healthy boys during pubertal transition. 
Adult levels were determined based on sera from 72 adult 
healthy males aged 18–40 years.
Results: An LC-MS/MS assay with limit of detection and 
limit of quantification (LOQ) of 0.06 and 0.15 ng/mL, 
respectively, and intra-assay CVs <9% in the relevant 
ranges was obtained. The LC-MS/MS compared well with 
the in-house immunoassay (Deming regression slope: 
1.28; Pearson correlation: R = 0.86). INSL3 concentra-
tions increased with pubertal maturation in healthy 
boys. INSL3 concentrations were above the LOQ in all 
samples from  the adult men. The mean (±2 SD range)
for serum INSL3 concentrations in the adult men was 
2.2 (0.5–3.9) ng/mL.
Conclusions: We have developed a robust and sensitive 
method suitable for quantitation of serum INSL3 in a 
clinical setting using LC-MS/MS instrumentation avail-
able in modern clinical laboratories. The method paves 
the way for future studies into the clinical role of serum 
INSL3 measurements.
Keywords: assay development; insulin-like factor 3 (INSL3); 
mass spectrometry.
Introduction
Insulin-like factor 3 (INSL3) is a 6.6-kDa peptide hormone 
and member of the insulin family [1]. In men, the testicular 
Leydig cells are the major, if not the only, source of INSL3, 
and measurement of circulating levels of INSL3  shows 
promise in the diagnostic evaluation of male subjects with 
andrological and developmental disorders [2]. Testoster-
one (T), the other major secretory product of the Leydig 
cells, is traditionally used as a biomarker for Leydig cell 
function and male hypogonadism. However, regulation of 
T is complex, and circulating T levels are influenced not 
only by testicular function but also by lifestyle (obesity, 
muscle mass, marital status, etc.), by hypothalamic and 
pituitary control and feedback and by metabolism, break-
down and interaction with binding proteins [3]. By con-
trast, INSL3  secretion is less influenced by other factors 
and is considered to directly reflect Leydig cell maturation 
and function [3]. INSL3 therefore has the potential to be a 
stable serum marker of Leydig cell function. In particular, 
serum INSL3 measurements could be clinically important 
in men with suspected hypogonadotropic hypogonadism. 
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Furthermore, INSL3  measurements are needed during T 
treatment to evaluate Leydig cell maturation and func-
tion, as T measurements reflect endogenous as well as 
exogenous T. Serum INSL3 may also be useful in boys with 
puberty delay to distinguish between constitutional delay 
and hypogonadotropic hypogonadism [1, 2]. Diagnostic 
implementation of serum INSL3 as a routine clinical bio-
marker in the andrological workup has been hampered 
by the lack of commercially available and reliable INSL3 
assays [2]. In this study, we present an in-house liquid 
chromatography-tandem mass spectrometry (LC-MS/
MS) method suitable for the large-scale studies needed to 
determine the clinical role of serum INSL3 measurements.
LC-MS/MS has become a standard method in clinical 
chemistry for the quantitation of small molecule analytes, 
such as steroids [4]. There is strong interest in expand-
ing the clinical role of MS to include circulating proteins 
and peptides. However, due to the large dynamic range of 
the plasma proteome [5], the detection limit of MS-based 
plasma proteomics is typically 1–10 ng/mL, and thus 
above the physiological range of many diagnostic pro-
teins, including most peptide hormones. The level of serum 
INSL3 in adult males is typically 0.5–2 ng/mL [6], and to 
our knowledge, INSL3 has not previously been detected in 
serum/plasma by MS, including highly sensitive plasma 
proteomics (i.e. human plasma proteome) [7]. Alternatively, 
using a variety of “non-proteomics methods”, MS has in a 
few cases successfully quantitated plasma peptides as low 
as the pg/mL range [8]. The mature form of INSL3 was origi-
nally purified from bovine testicular tissue and was char-
acterized as an A-B heterodimer that could be separated 
by chemical reduction of the disulfide bridges after which 
the A- and B-chains were detected by matrix-assisted laser 
desorption ionization-time of flight mass spectrometry 
(MALDI-TOF MS) [9]. The smaller A- and B-chains are likely 
better suited for LC-MS/MS analysis than the intact INSL3 
A-B heterodimer. Here we develop and validate a robust 
and sensitive method whereby the human INSL3 A-chain is 
released from the INSL3 A-B heterodimer by reduction and 
alkylation and quantitated in serum by LC-MS/MS.
Materials and methods
Serum samples
The serum samples (n = 97) from 12 healthy Danish boys (9–15 years 
old) were from a longitudinal substudy of the COPENHAGEN puberty 
study approved by the Danish Data Protection Agency (2015-41-4494) 
and by the Ethics Committee (KF 01 282,214 and V200.1996/90). For 
these boys, INSL3 levels measured by a non-commercial in-house 
immunoassay have previously been published [10]. The serum sam-
ples (n = 72) from adult healthy Danish men (18–40 years old) were 
from a study of testicular function approved by the Ethical board of 
the Danish Capital Region (permit number H-2-2012.092) [11]. Serum 
was collected and pooled from volunteering healthy males (n = 3, 
age: 35–55 years) and females (n = 3, age: 55–65) at Rigshospitalet for 
use in assay development.
Chemicals
Proteins were reduced with dithiothreitol (DTT) (Sigma Aldrich, 
 Denmark) and alkylated using iodoacetamide (IAM) (Sigma). Lys-C/
trypsin (Promega, Denmark) was used for protein digestion. Milli-Q 
water was from a Millipore Synthesis A10 system (Billerica, MA, USA). 
All chemicals (ammonium biocarbonate [NH4HCO3], ammonium ace-
tate [NH4AC], ethanol [EtOH], acetonitrile [ACN], formic acid [FA] and 
tri-flouro acetic acid [TFA]) were of laboratory grade. Human recom-
binant IGF1, IGF2, insulin and bilirubin were from Sigma. Intralipid 
was from Fresenius Kabi (Copenhagen, Denmark).
Calibrant and internal standard
Lyophilized and recombinant human INSL3 (50 μg, R&D Systems, 
Abingdon, UK, bottled 12/15/2014) was dissolved in water:acetonitrile 
(95:5 v/v) and quantitated by triplicate amino acid analysis on 
a BioChrom 30  system (Alphalyse A/S, Odense, Denmark). The 
INSL3 stock was diluted in female serum and calibrants, and quality 
control (QC1–3) samples were stored at −20 °C. Lyophilized synthetic 
INSL3 A-chain peptide was labeled at prolines 6 and 25 (13C6, 15N), and 
arginine 8 (13C6, 15N4) (Pepscan, The Netherlands) was dissolved in 
water:acetonitrile (95:5 v/v) and used as internal standard (IS).
Sample preparation
The sample reagent (100 mL) was prepared daily by mixing 15 mL of 
1.5 M NH4AC, pH: 8.6 with 85 mL of EtOH and spiked with IS. Serum, 
calibrant and QC samples (150 μL) were transferred to tubes (LoBind, 
Eppendorf), sample reagent was added (350 μL) and the samples were 
mixed (600 × g for 10 s and 100 × g for 10 min) and left at −20 °C for 
1 h and centrifuged (12.700 × g, 10 min, 4 °C). The supernatant (400 μL) 
was collected and reduced by addition of 5 μL DTT (final conc. 1 μM) 
and left in shaker for 30 min (100 × g, 60 °C). Alkylation was carried out 
by addition of 5 μL IAM (final conc. 2 μM), and the samples were left 
in the dark for 30 min (room temperature). Subsequently, the samples 
were evaporated using nitrogen flow (45 °C, 90 min). The dried pellet 
was dissolved in 90 μL 50 mM NH4HCO3 (pH 8) and placed in a shaker 
for 5 min (100 × g, 60 °C) and centrifuged (12.700 × g, 10 min, 4 °C). The 
supernatant (80 μL) was transferred to vials.
LC-MS/MS of serum INSL3
Samples were kept at 10 °C and injected (65 μL) using an HTS PAL 
autosampler (CTC Analytics AG, Switzerland). LC-MS/MS analysis 
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was performed on a Dionex UltiMate 3000 UHPLC system with inte-
grated Transcend TLX TurboFlow coupled to a triple quadrupole 
mass spectrometer (TSQ Vantage, Thermo Scientific, USA) con-
trolled by Aria MX 2.1 and Xcalibur 3.0.63 software (ThermoFinnigan, 
USA). The turboflow column was Cyclone-P Turboflow (proprietary 
stationary phase, 50  mm × 0.5  mm, Thermo) kept at 25 °C, and the 
analytical reverse phase-column was Kinetex (reverse phase C18, 
50 mm × 2.1 mm, 2.6 μM, 100 Å, Phenomenex) with Security Guard 
Ultra (reverse phase C18 filter, 2.1 mm × 4 mm, 2.6 μM Phenomemex) 
kept at 45 °C. Eluent A was 0.2% FA in MQ water, and eluent B was 
100% ACN. The total runtime was 10.1 min with a solvent flow on the 
eluting side of 0.3 mL/min, and the gradient increased from 12% to 
50% solvent B. See Supplemental Figure 1 for details about the LC 
method. The MS instrument was equipped with a heated electrospray 
ionization probe operated in positive mode. The spray voltage was 
3500 V. Nitrogen was used as sheath gas, aux gas and sweep gas at 
45, 40 and 0 (arbitrary units), respectively. The ion transfer tube was 
kept at 350 °C, and the vaporizer temperature was 425 °C. A cycle time 
of 0.2 s was used, and resolution (FWHM) at both Q1 and Q3 was 0.7. 
Argon was used as collision gas at a pressure of 2 mTorr and Chrom 
filter = 3. Collision energies were 25 V and 30 V, and s-lens settings 
were 150 and 160 for transitions 1 (T1) and 2 (T2), respectively.
Validation experiments
Several method parameters were determined according to CLSI 
guidelines [8]. To evaluate linearity, INSL3  was spiked in female 
serum pool. Nine concentrations were analyzed in triplicates, and 
the linearity of two INSL3 transitions was assessed: T1 (Q1:1002.8, 
Q3:  439.1 [y3 + 1]) and T2 (Q1:1002.8, Q3: 279.1 [y2 + 1]). Assay selec-
tivity was evaluated by spiking human serum with members of the 
insulin family of peptides and with intralipid (0, 5, 10, 15 and 20 mM) 
(to imitate samples with elevated triglycerides) or with bilirubin (0, 
50, 100, 150, 200 and 300 mM) (to imitate samples with Icterus). Limit 
of detection (LOD) and limit of quantification (LOQ) were determined 
in female serum spiked with INSL3 to produce standard curves of 
five points (0.0, 0.1, 0.15, 0.2, 0.25 and 0.3 ng/mL). LOD was defined 
as 4 × SD from the average zero concentration. LOQ was defined as 
the lowest concentration level where the results of five measure-
ments resulted in a deviation below 20%. The TurboFlow LC-MS/MS 
method was compared to a non-commercial time-resolved fluores-
cence immunoassay (TRFIA) by comparing the results obtained in 
97 serum samples collected from 12 boys during pubertal transition 
(9–14 years), which previously had been analyzed by the TRFIA [10] 
and since stored at −80 °C for 3 years. Serum INSL3 was also meas-
ured in samples collected from 72 healthy adult men (age 18–40). The 
serum from healthy boys and adult men (n = 169 samples) was previ-
ously analyzed for T and luteinizing hormone (LH) [10, 11]. Currently, 
there is no available certified reference material for INSL3, and three 
QC samples (0.25, 1.0 and 3.0 ng/mL, respectively) were prepared in-
house by spiking female serum pool with recombinant INSL3. The 
QC samples were analyzed five times in one batch, and three times in 
each of five batches. Stability of serum INSL3 was assessed in serum 
stored for up to 3 days at 4 °C or 27 °C. Samples were exposed to four 
cycles of freezing and storage (24 h at −20 °C). The matrix effect was 
assessed by diluting the male serum pool (2.5  ng/mL) with pooled 
female serum from 2.5 to 0.125 ng/mL and, secondly, by spiking a pool 
of female serum with increasing amounts of recombinant INSL3 from 
0.1 to 5.0 ng/mL. Recovery was further examined in 10 serum samples 
from healthy boys with endogenous INSL3 of 0.15–0.3 ng/mL that 
were spiked with recombinant INSL3 corresponding to additional 
1.0 or 5.0 ng/mL.
MALDI-TOF MS and Q-TOF MS of recombinant INSL3
Proteins were treated by solid-phase extraction (zip-tips, C-4, 
 Millipore) before MALDI-TOF MS (Autoflex, Bruker, Bremen, 
 Germany). NanoLC-Q-TOF MS was performed on an Ultimate 3000 
nano-LC system (Thermo) coupled to a MicrO-TOF QII MS instru-
ment (Bruker). Peptides were trapped on a C18 precolumn (300 μm 
inner diameter × 5  mm; Dionex) with a flow rate of 20 μL/min sol-
vent C (1% ACN, 0.1% TFA) for 10 min and switched online with the 
analytical C18 column (75 μm inner diameter × 50 cm; PepMap C18, 
Dionex), and eluted with flow rate 200 nL/min and a gradient of 
4%–90% solvent B over 30 min (solvent A: 0.1% FA; solvent B: 0.1% 
FA, 80% ACN). Region m/z 100–2500 was collected for MS1 analysis. 
Distiller software (Mascot V2.5.1, UK) was used for peak process-
ing and database search in the Swiss Prot Database with oxidation 
of methionine as variable modification and no proteolytic diges-
tion. The precursor and fragment mass deviations were 60 ppm and 
0.1 Da, respectively, with FDR <1%.
Statistics
Descriptive analyses (R, Deming regressionn and Pearson correla-
tion) were performed using Excel 2010 (Microsoft). See details in 
Supplemental Table 1.
Results
Assay development
MALDI-TOF MS of recombinant INSL3 identified a mass 
peak of m/z 6785.9, in agreement (>99.9%) with the mass 
of the human INSL3 A-B heterodimer (theoretical MW 
6786.9 Da) (Figure 1A). Reduction and alkylation resulted 
in the disappearance of the signal from intact INSL3 and 
emergence of three mass peaks (Figure 1B). The mass 
peaks of m/z 3006.3 and 4130.2 correspond well (>99.9%) 
with the MWs of the alkylated A- and B-chains (theo retical 
MW 3005.3 and 4129.7 Da, respectively) (Figure 1B). We 
have no explanation for the emergence of the MALDI-TOF 
MS mass peak with m/z 2945.3 (Figure 1B). The sequence 
of the recombinant alkylated INSL3 A-chain was veri-
fied by nanoLC-Q-TOF MS (Figure 1C). Database search 
(Blast and Uniprot) revealed that the sequence of human 
INSL3 A-chain is unique and contains no known post-
translational modifications. Next, combinations of the 
alkylated INSL3 A-chain (in charge states from +3 to +6) 
and the theo retical B and Y product ions (charge states 
Brought to you by | The Royal Library (Det Kongelige Bibliotek) - National Library of Denmark / Copenhagen University Library
Authenticated
Download Date | 5/31/18 8:39 AM
4      Albrethsen et al.: Serum INSL3 measured by MS
+1, +2 and +3) were tested on high throughput TurboFlow 
LC-MS/MS (see Supplemental Figure 2). Two transitions of 
the triple-charged and alkylated INSL3 A-chain performed 
best and are subsequently referred to as T1 (Q1:1002.8, 
Q3: 439.1 [y3 + 1]) and T2 (Q1:1002.8, Q3: 279.1 [y2 + 1]). An 
overview of the analytical strategy is provided in Supple-
mental Figure 3. Due to its low abundance, we were not 
able to detect INSL3 in human serum using proteomics 
methods (Supplemental Figure 4).
Selectivity
A synthetic and stable isotope-labeled human INSL3 
A-chain was used for IS (Supplemental Figure 5), and the 
IS co-eluted with INSL3 detected in pooled serum from 
males (Figure 1D). No signal for T1 or T2  was observed 
when measuring pooled female serum (Supplemental 
Figure 6A), as is expected because serum INSL3 is often 
low, or undetectable, in female serum (<0.01 ng/mL). 
Second a signal was observed for both T1 and T2  when 
measuring female serum spiked with INSL3, but not 
after spiking with other related peptides (Supplemental 
Figure 6B–E) and only after both reduction and alkylation 
(data not shown). Together these observations support 
that the assay selectively detects the alkylated INSL3 
A-chain after release from the recombinant or endogenous 
INSL3 A-B heterodimer.
Sensitivity
The method was validated in accordance with CLSI 
guidelines for LC-MS/MS assays [8]. First, the stock solu-
tion of recombinant human INSL3  was quantitated by 
amino-acid analysis (Supplemental Figure 7), and good 
Figure 1: Identification of LC-MS/MS transitions for serum INSL3.
MALDI-TOF MS analysis of the intact INSL3 A-B heterodimer (A), and of the individual INSL3 A- and B-chains after reduction and alkylation 
(B). NanoLC-Q-TOF MS of the alkylated INSL3 A-chain (C). TurboFlow LC-MS/MS of serum INSL3 (1.0 ng/mL) and internal standard peptide 
spiked in human serum, using transitions 1 and 2 (D).
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linearity of calibration curves was obtained by monitoring 
T1 and T2. There was no significant difference (p > 0.98, 
t-test, two-sided), or systematic difference (residual plot), 
between linear and higher-order polynomial fitting in the 
range from 0.15 to 5.0 ng/mL (Supplemental Figure 8). 
LOD and LOQ were respectively 0.14 and 0.25 ng/mL (ave. 
S/N: 134) for T1, and 0.06 and 0.15 ng/mL (ave. S/N: 68) 
for T2 (Table  1) (Supplemental Figure 9A). Accordingly, 
T2 was chosen for quantitation, whereas as T1 was used as 
qualifier transition for INSL3 measurements. The method 
was only validated in human serum, but endogenous 
INSL3 was detected in plasma (Supplemental Figure 9B).
Method comparison
The results from TurboFlow LC-MS/MS of 97  serum 
samples were compared to a non-commercial TRFIA 
[10]. All 97  samples contained sufficient INSL3 levels to 
be measured by the TRFIA (LOQ: 0.01 ng/mL, CV <10%) 
[6,  10,  12]. Scatterplot of LC-MS/MS vs. TRFIA in all 
97 samples is shown in Supplemental Figure 10A. Accord-
ing to TRFIA, 30  samples contained INSL3 levels below 
the LOQ (0.15 ng/mL) of the LC-MS/MS method. For the 
67  samples with INSL3 >0.15 ng/mL, the Deming regres-
sion slope was 1.28, the Pearson correlation was R = 0.86 
(Figure  2A and Supplemental Table 1) and two of the 
67  samples deviated more than 1.96 times the standard 
deviation in a difference plot (Figure 2B). Of the remaining 
30 samples, 26 contained less than the LOQ when meas-
ured by the LC-MS/MS method. In four samples (contain-
ing 0.03, 0.12, 0.09 and 0.14 ng/mL, respectively, according 
to TRFIA), the concentration of INSL3 was slightly above 
the LOQ with LC-MS/MS (0.2, 0.2, 0.25 and 0.3 ng/mL, 
respectively) (Supplemental Figure 10B).
INSL3 as a marker of Leydig cell functionality
The mean serum INSL3  was 2.2 ng/mL (SD = 0.8) 
in 72  healthy males giving a 95% confidence range 
(±1.96 × SD) of 0.5–3.9 ng/mL (Figure 2C). There was no 
significant difference between INSL3 levels in the young 
(n = 32, age: 18–20  years) and middle-aged (n = 40, age: 
21–40  years) subgroups of men (t-test for means, two-
sided, p = 0.19). In the boys, pubertal onset was defined as 
testicular volume >3 mL, and testicular volume increased 
with age [10]. INSL3, LH and T appeared to increase simul-
taneously during pubertal transition in healthy males 
(Figure 3A–C).
Additional assay validation
The intra-assay (15  measurements) and inter-assay (45 
measurements) CVs were below <15% (Table 1). Intralipid 
and bilirubin showed with no significant impact on serum 
Table 1: Validation of Turboflow LC-MS/MS of serum insulin-like 
factor 3 (INSL3).
LOD, ng/mL 0.06
LOQ, ng/mL 0.15
Linear range, ng/mL 0.15–5.0
Intra-assay CV, % 5.4–8.8
Inter-assay CV, % 11.7–14.5
Recovery, % 87–130
0
0
1
2
3
4
5
6
–1.5
–0.5
0.5
1.5
0
–1.96 SD:
–0.924
0.211
+1.96 SD:
Mean:
–0.502
1 2
y = 1.28x – 0.018
R = 0.86
INSL3 by TRFIA, ng/mL Ave. INSL3 by TRFIA and LC-MS/MS, ng/mL
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Figure 2: LC-MS/MS of serum INSL3.
Comparison of TRFIA and Turboflow LC-MS/MS-based quantitation of serum INSL3 (n = 67) shown as scatterplot (A) and difference plot (B). 
Turboflow LC-MS/MS of serum INSL3 from healthy adult males (n = 72) (C).
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INSL3 (Supplemental Figure 11). Although INSL3  seemed 
to decrease slightly after 2  days storage at 27 °C, this was 
non-significant (Supplemental Figure 12), and there was 
no effect from freezing and thawing. Spiking and dilution 
curves were linear (R2 > 0.98) with almost similar slopes 
(Supplemental Figure 13), and the recovery was 87%–130% 
(Table 1). There was no carryover observed on both T1 or T2 
in subsequent blank measurement when female serum was 
spiked with 20 ng/mL INSL3 (data not shown). As QC, there 
was good correlation for the results obtained by monitoring 
the qualifier (T1) and the quantifier (T2) transition (R2 > 0.86) 
in the 72 adult men (Supplemental Figure 14).
Discussion
We present a robust and sensitive LC-MS/MS-based 
method whereby the alkylated INSL3 A-chain is quan-
titated in serum, as surrogate for the INSL3 A-B hetero-
dimer. The assay sensitivity is well suited for serum 
INSL3  measurements in adult males (LOQ = 0.15 ng/mL). 
The reproducibility of the method was <15%, and the pre-
sented in-house method can be performed on LC-MS/MS 
instruments available in hospital laboratories (i.e. UHPLC 
coupled with Triple-Q MS). The workload is only slightly 
higher as compared to the in-house LC-MS/MS-based 
method we use for routine measurements of andro-
gens [13]. We hypothesize that INSL3 determination will 
improve existing diagnostic procedures for male patients 
with suspected hypogonadotropic hypogonadism. As a 
next step, the biological variation of serum INSL3 should 
be examined in a large number of healthy males. Studies 
should also be performed to describe the dynamic rela-
tionship between serum INSL3 and other hormones in 
testicular disorders and puberty. The receptor for INSL3, 
relaxin family peptide receptor 2 (RXFP2), is widely 
expressed, and INSL3 may be important for germ cell sta-
bility [14] and bone metabolism [15]. Future studies may 
unravel additional endocrine roles of INSL3.
The results obtained with this newly developed 
LC-MS/MS method correlate well to those obtained with 
a non-commercial TRFIA. The TRFIA has been optimized 
for improved sensitivity [6, 10, 12] and was successfully 
applied in several studies, including a study of a large 
serum cohort from adult males [6] and for sensitive analy-
sis of low levels of INSL3 in women serum [12]. According 
to both LC-MS/MS and TRFIA, serum INSL3 increased in 
healthy boys during pubertal transition. Overall, slightly 
higher serum INSL3 levels were obtained with the 
LC-MS/MS-based method, and second, the two methods 
appeared to deviate relatively more in the high concen-
tration range, although only two measurements fell 
outside the 1.96 SD limits in a difference plot. For optimal 
method comparison with the TRFIA, we used the same 
recombinant INSL3 peptide spiked in a similar matrix 
(pool of serum from women) as calibration solution, 
and the stock solution of INSL3 peptide was accurately 
quantitated by amino acid analysis. We propose that the 
bias in measured levels between the LC-MS/MS and the 
TRFIA method could be due to either the preparation of 
the calibrants or the structural changes of INSL3 during 
sample processing that may influence detection by either 
assay (dilution, storage, etc.). After the TRFIA analysis, 
the serum was stored for 3 years at −80 °C before LC-MS/
MS analysis, but this probably does not explain the 
slightly higher values obtained in the later measure-
ment. Recombinant standard protein and synthetic ISs 
may contain minor contaminants, but these are unlikely 
to interfere with assay quantitation in LC-MS/MS. The 
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Figure 3: Change of serum INSL3, testosterone and LH with age.
TurboFlow LC-MS/MS of serum INSL3 in males (age 9–40 years, n = 169) (A), compared to previously measured Ref. [10, 11] testosterone and 
LH in the same samples (B and C).
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average serum INSL3 in our 72 healthy adult Danish men 
was 2.2 ng/mL (0.5–3.9). In another study, using TRFIA, 
the average level measured in healthy adult males (aged 
35–44 years) was 1.3 ng/mL (0.3–3.5), and declined with 
age [6]. Two other studies using TRFIA reported aver-
ages of 0.9–0.99 ng/mL in adult healthy men [16, 17]. In 
addition to differences associated with calibration and 
methods, the differences in average INSL3 observed in 
healthy men with LC-MS/MS and TRFIA could reflect 
cohort differences. According to a commercial ELISA, 
the average was 1.5 ng/mL in healthy males [18] and 
2.7 ng/mL in patients with Klinefelter syndrome [19], 
whereas the commercial RIA measures up to 10-fold 
lower levels of serum INSL3 than the other three assays 
[20–22]. Thus, discrepancies exist using the commer-
cially available assays. In the future, reference material 
for INSL3 should be developed for interlaboratory com-
parisons, and a matrix of organic solution (i.e. 20% ACN) 
may be more practical for calibration. It remains to be 
seen whether the LC-MS/MS method is sufficiently sensi-
tive for detection of earliest stages of male puberty. In 
boys, serum INSL3 increased dramatically at the onset 
of puberty, but it cannot be excluded that in some boys 
serum INSL3 may be present <LOD at the earliest stage of 
puberty. Interestingly, LC-MS/MS of INSL3  may demon-
strate better analytical sensitivity in plasma as compared 
to serum (Supplementary Figure 9A).
Serum INSL3 was quantitated by LC-MS/MS using the 
triple-charged and alkylated INSL3 A-chain as precursor. 
A C-terminal product ion (y2[+1], m/z 279.1) provided best 
sensitivity and results from proline-directed fragmenta-
tion [23] and is predicted to provide a particularly strong 
signal [24]. The presented analytical principle may be 
applicable to other members of the insulin-like family 
of peptides and to their therapeutic analogues [25]. In 
comparison, LC-MS/MS-based quantitation of human 
insulin is also possible by using C-terminal fragments 
as product ions, but from the B-chain [26]. The alkylated 
INSL3 B-chain was detected by MALDI-TOF MS, but not 
by LC-MS/MS, probably due to the extreme hydropho-
bicity (pI: 9.6) of the B-chain resulting in low solubility 
and poor LC separation. In a previous study, reduction 
of INSL3 from bovine testicular tissue produced two 
forms of the INSL3 B-chain possibly due to alternative 
N-terminal cleavage, whereas the A-chain was identified 
in a single form only [9], and thus, the A-chain could be 
the better target for quantitation of INSL3 by LC-MS/MS. 
We believe that INSL3 is fully denatured after 30 min at 
60 °C in 80% ethanol, and thus, all cysteines will there-
fore be exposed for reduction, but this requires further 
investigation. Future studies should also examine using 
stable isotope-labeled and recombinant INSL3 protein, 
or recombinant INSL3 from another species, as IS as 
this may allow for further compensation of potential 
assay variation associated with reduction of INSL3 and 
other analytical steps. The selectivity of the LC-MS/
MS method was demonstrated by showing no signal in 
samples spiked with other recombinant proteins belong-
ing to the insulin-like hormone superfamily. Further-
more, 30  serum samples that according to the TRFIA 
contained INSL3 below the LOQ (<0.15 ng/mL) were also 
in the LC-MS/MS confirmed as being below, or in four 
cases slightly above, the LOQ. It is possible that both the 
mature form of INSL3 (6.6  kDa) and the pro-form(s) of 
INSL3 (12–14 kDa) are secreted from mammalian Leydig 
cells [1]. The available immunoassays recognize the cor-
rectly folded INSL3 B-chain that is present in all isoforms. 
The LC-MS/MS method instead measures the free INSL3 
A-chain that can be released from the A-B  heterodimer 
(6.6 kDa) by breaking of disulfide bridges, but not from 
pro-INSL3 (12–14  kDa) where the A-chain is linked to 
the C-domain by a peptide bond (see Supplemental 
Figure  3). The correlation between TRFIA and LC-MS/
MS measurements therefore support that in humans the 
majority, if not all, of the circulating INSL3 is present as 
the A-B heterodimer in agreement with the structure of 
INSL3 extracted from bovine testis [9]. Hypothetically, 
the A-chain could possibly also be released from another 
(unknown) structural form of endogenous INSL3.
In conclusion, INSL3  measurements could be clini-
cally relevant for the detection of Leydig cell impairment 
in the heterogenous group of males with andrological 
disorders [1, 2]. The presented method adds serum INSL3 
to the panel of diagnostic male reproductive hormones 
(LH, follicle-stimulating hormone, T, inhibin B and anti- 
Müllerian hormone) that can be analyzed in large-scale 
studies. However, future studies will have to confirm the 
clinical role of serum INSL3 measurements.
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